Takeda Appoints Former Lilly Executive Rhonda Pacheco as President of U.S. Business

(Source: Yidu Medicine)

Source: Yidu Medicine

2025Year9Month11Day, Takeda Pharmaceutical Company Limited (TSE：4502/NYSE：TAK) Announced Significant Personnel Appointment in Cambridge, Massachusetts, USA, Finalizing the New Leader for U.S. Operations, Drawing Wide Attention in the Pharmaceutical Industry.

The announcement shows that the former Vice President of Eli Lilly's U.S. Cardiometabolic Health DivisionRhonda PachecoWill join Takeda. Since2025Year9Month29Starting from the day, she will officially assume the position of President of Takeda's U.S. Business Unit and join Takeda’s Executive Team, deeply participating in the group's core decision-making.

As a core business unit in Takeda's global key markets, the development of the U.S. business division is directly tied to the group's overall strategic layout. This choiceRhonda PachecoTaking over this important position is precisely due to the high alignment with Takeda's current strategic needs. During his tenure at Eli Lilly and Company,PachecoHas accumulated rich experience in pharmaceutical commercialization and team management, not only leading the management of multiple complex product portfolios but also successfully promotingGLP-1The launch of such products, along with their robust commercial performance, will inject new momentum into Takeda's U.S. business growth through their professional expertise and industry resources.

Notably, this personnel adjustment also involves a long-term succession plan for Takeda's senior executives. Previously,2025Year1In the month, the Takeda Board officially announced that the current President of U.S. Business DivisionJulie KimWill be in2026Year6Monthly HandoverChristophe Weber, appointed as the new President andCEO. WithRhonda Pacheco's succession,Julie KimWill no longer serve as the President of the U.S. Business Division, and will instead focus entirely on...CEOTransition preparation work. During this period, she will also temporarily take over as the head of the Global Product Portfolio Department, and by deeply participating in the management of the group's core business sectors, lay the foundation for subsequently taking full charge of the group’s management work.

According to publicly available information, the newly appointed President of U.S. OperationsRhonda PachecoWith a solid background in professional and management education. A native of Massachusetts, she graduated from Duke University's Fuqua School of Business with a Master of Business Administration (MBA).MBA) degree; simultaneously holds a Doctor of Pharmacy degree from the University of Rhode Island,During her studies, she also served as the captain of the university's women's basketball team, demonstrating diverse capabilities and qualities.

This personnel adjustment by Takeda Pharmaceutical Company Limited is not only a significant measure for the renewal of the company's senior management, but also reflects its emphasis on the development of business in the U.S. market and considerations for future strategic layout. WithRhonda PachecoThe addition ofJulie KimWith the role transition, Takeda Pharmaceutical Company Limited is entering a new phase of development. Its subsequent business activities and strategic implementation are worth continuous attention from the industry.